Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Edema 1Brain Neoplasms 1Brain Edema 1Astrocytoma 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Corticotropin-Releasing Hormone × Clear all
NCT00226668 2008-01-03

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Celtic Pharma Development Services

Phase 3 Withdrawn
120 enrolled
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡